Copilot
Your everyday AI companion
About 5.2M results
    • elaherehcp.com
      http://www.elaherehcp.com

      Elahere™ (mirvetuximab | soravtansine-gynx) | Elahere Support

      Elahere™ (mirvetuximab | soravtansine-gynx) | Elahere Support

      Ad
      http://www.elaherehcp.com
      From this website
    • elahere.com
      https://www.elahere.com

      Elahere™ (mirvetuximab | soravtansine-gynx)

      Elahere™ (mirvetuximab | soravtansine-gynx)

      Ad
      https://www.elahere.com
      From this website
  3. People also ask
    Who is elahere used for?
    ELAHERE® is indicated for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Select patients for therapy based on an FDA-approved test.

    AbbVie Receives Positive CHMP Opinion for Mirvetuximab Soravtansin…

    finance.yahoo.com
    Will elahere be approved for ovarian cancer?
    By Colin Kellaher AbbVie on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of its recently acquired Elahere cancer drug for certain adults with ovarian cancer.

    AbbVie Gets CHMP Backing for Elahere in Ovarian Cancer

    marketwatch.com
    Can elahere cause ocular adverse reactions?
    ELAHERE can cause severe ocular adverse reactions, including visual impairment, keratopathy (corneal disorders), dry eye, photophobia, eye pain, and uveitis. Ocular adverse reactions occurred in 59% of patients with ovarian cancer treated with ELAHERE.

    AbbVie Receives Positive CHMP Opinion for Mirvetuximab Soravtansin…

    finance.yahoo.com
    Does AbbVie own elahere?
    Elahere, which won initial U.S. Food and Drug Administration approval in 2022 for platinum-resistant ovarian cancer, was the key asset in AbbVie's $10.1 billion acquisition of biotech ImmunoGen that closed earlier this year. AbbVie reported global Elahere net revenue of $128 million in the second quarter.

    AbbVie Gets CHMP Backing for Elahere in Ovarian Cancer

    marketwatch.com
    Feedback
  4. MarketWatch
    https://www.marketwatch.com/story/abbvie-gets-chmp...

    AbbVie Gets CHMP Backing for Elahere in Ovarian Cancer

  5. PR Newswire
    https://www.prnewswire.com/news-rele…

    AbbVie Receives Positive CHMP Opinion for …

    WEB2 days ago · ELAHERE® (mirvetuximab soravtansine-gynx) U.S. INDICATION and IMPORTANT SAFETY INFORMATION ... Some statements in this news release are, or may be considered, forward …